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Introduction
 Psychiatric illnesses are associated with a high 
prevalence of therapeutic failure, drug-associated side 
effects, and recurrent conditions. In psychiatry, as in 
other diseases, there is a high interindividual variabil-
ity in drug responses for efficacy, tolerability, and safety, 
which is determined by patient factors such as illnesses, 
sex, age, ethnicity, and genetic variability, and by envi-
ronmental factors, including concomitant medication, 
smoking, and/or diet.1,2 This variability in drug response 
is affected by variability in pharmacokinetics, ie, drug 
disposition (absorption, distribution, metabolism and 
excretion [ADME]), leading to a variability in plasma 
concentration of the active drug, but also by variabil-
ity in pharmacodynamics, ie, the interaction of the drug 
with its target site (such as enzymes, receptors, and trans-
porters).1 Personalized prescribing can be expressed as 
personalized dosing and/or drug selection, taking into 
account genetic, as well as environmental and personal, 
variables.3 This review discusses the present and future 
use of pharmacogenetics in psychiatry, which, combined 
with careful clinical evaluations and other tools such as 
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The use of pharmacogenetic tests was already being 
proposed in psychiatry in the early 2000s because genet-
ic factors were known to influence drug pharmacoki-
netics and pharmacodynamics. However, sufficient lev-
els of evidence to justify routine use have been achieved 
for only a few tests (eg, major histocompatibility com-
plex, class I, B, allele 1502 [HLA-B*1502] for carbamaze-
pine in epilepsy and bipolar disorders); many findings 
are too preliminary or, when replicated, of low clinical 
relevance because of a small effect size. Although drug 
selection and dose adaptation according to cytochrome 
P450 genotypes are sound, a large number of patients 
need to be genotyped in order to prevent one case of 
severe side effect and/or nonresponse. The decrease in 
cost for genetic analysis shifts the cost:benefit ratio to-
ward increasing use of pharmacogenetic tests. However, 
they have to be combined with careful clinical evalua-
tions and other tools (eg, therapeutic drug monitoring 
and phenotyping) to contribute to the general aim of 
providing the best care for psychiatric patients.  
© 2016, AICH – Servier Research Group Dialogues Clin Neurosci. 2016;18:313-322.
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therapeutic drug monitoring (TDM) and phenotyping, 
can help provide the best care for psychiatric patients. 
This review is based on arbitrarily selected pharmaco-
genetic studies. The topic of TDM is covered in detail by 
a consensus article4 and is not discussed here. Whereas 
our review has a stronger focus on the clinical applica-
tions and usefulness of pharmacogenetics tests, the ar-
ticle by Eum et al in this issue (p 323) provides a much 
more detailed elaboration of currently commercially 
available tests.
Pharmacokinetics genes
Among pharmacokinetics proteins, the members of the 
cytochrome P450 (CYP) family display large interin-
dividual and interethnic variability in activity, control-
ling the metabolism of many psychotropic drugs. More 
than 50 CYP enzymes have been identified in humans, 
but more than 90% of all drugs are metabolized by 
only a few of them—CYP1A2, CYP2B6, CYP2C8/9, 
CYP2C19, CYP2D6, CYP2E1, and CYP3A4/5. The US 
Food and Drug Administration (FDA) table of phar-
macogenetic markers in drug labels5 contains more 
than 135 drugs, a fifth used in psychiatry, most of them 
CYP2D6-dependent drugs.
 Various CYP2D6-activity phenotypes exist, includ-
ing poor, intermediate, extensive, and ultrarapid metab-
olizers (PMs, IMs, EMs, and UMs), with PMs having no 
functional alleles, IMs being heterozygous for an active 
and an inactive allele or having two alleles with reduced 
activity, EMs being wild-type with two active alleles, and 
UMs having an amplification of functional alleles (3 to 
13 copies).6,7 The PM status can be genotyped, with 5 to 
10 single-nucleotide polymorphisms (SNPs) accounting 
for 95% to 99% of the variability. However, more than 
100 variants and subvariants have been described for 
CYP2D6,8 with a strong influence by geographic and 
ethnic factors, which should be taken into account.
 Some studies showed that CYP2D6 might influence 
the metabolism of endogenous compounds, such as the 
ligand for the cannabinoid receptor anandamide,9 or 
the production of serotonin,10 with a higher platelet se-
rotonin concentration in UMs than in EMs and PMs.11 
It has been suggested that this could lead to variations 
in personality, neurocognitive function, and vulnerabil-
ity to psychopathology, including suicidality.12,13 Indeed, 
a high occurrence of the CYP2D6 UM phenotype has 
been found in suicide cases14-16; this association could 
be due to failure of treatment with drugs metabolized 
by CYP2D6 but also to the metabolism of endogenous 
substrates. However, CYP2D6 is not a useful predictor 
of psychiatric symptoms and/or disorders.
 On the other hand, many studies have shown a 
strong influence of CYP2D6 activity on the pharma-
cokinetics of psychotropic drugs. These include drugs 
for attention-deficit/hyperactivity disorder (eg, atom-
oxetine); antidepressants, such as tricyclics (TCAs) or 
tetracyclics (TeCAs) that are serotonin and/or norepi-
nephrine reuptake inhibitors (eg, amitriptyline, clomip-
ramine, desipramine, doxepine, imipramine, maproti-
line, nortriptyline, or trimipramine), selective serotonin 
reuptake inhibitors (SSRIs; eg, citalopram, escitalo-
pram, fluoxetine, fluvoxamine, or paroxetine), and se-
rotonin-norepinephrine reuptake inhibitors (SNRI; 
eg, duloxetine or venlafaxine); other antidepressants 
(eg, mianserin or mirtazapine); and antipsychotics (eg, 
aripiprazole, haloperidol, levomepromazine, perphen-
azine, risperidone, thioridazine, or zuclopentixol).6,17 Of 
note, the activity of CYP2D6 and other CYP isoforms 
can be blocked; several compounds, including some of 
the abovementioned drugs, are strong CYP2D6 inhibi-
tors (eg, levomepromazine, paroxetine, and fluoxetine) 
and can potentially transform the phenotype from CY-
P2D6 EM to PM.2 On the other hand, CYP2D6 activity 
cannot be induced in contrast to other CYP isoforms 
(one Website listing drugs with their CYP-mediated 
metabolism, as well as important metabolic interac-
tions, can be found in ref 18).
 Optimal therapeutic ranges for drug concentrations 
in plasma have been demonstrated for TCAs, such as 
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amitriptyline, clomipramine, doxepin, imipramine, and 
trimipramine,4 with UMs at increased risk of therapeu-
tic failure and PMs at increased risk of toxicity (in par-
ticular, for cardiac and anticholinergic effects). A higher 
risk of side effects has been observed in patients with at 
least one nonfunctional CYP2D6 allele than in those 
with two functional alleles.7 The first genotype-based 
dose recommendations for antidepressants, including 
amitriptyline, were proposed by Kirchheiner et al in 
2001.19 More recently, the Pharmacogenetics Working 
Group from the Royal Dutch Association for the Ad-
vancement of Pharmacy developed guidelines.20 Also, 
the Clinical Pharmacogenetics Implementation Con-
sortium (CPIC) of the National Institutes of Health’s 
Pharmacogenomics Research Network developed a de-
tailed guideline—updated periodically21—for CYP2D6 
and CYP2C19 genotypes and dosing of TCAs.7 For ex-
ample, in the treatment of depression with amitripty-
line, the CPIC recommends consideration of an alterna-
tive drug for CYP2D6 UMs and PMs.
 Personal dosing in psychiatry according to CYP 
genotype is best adapted for TCAs.7 However, in psy-
chiatry, the impact of such a strategy is limited since 
the prescription of TCAs has greatly decreased since 
the introduction of newer antidepressants (TCAs being 
mainly used nowadays at lower doses for pain manage-
ment). Personalized prescribing according to CYP2D6 
genotype has been proposed for more recent antide-
pressants, such as SSRIs (eg, paroxetine, fluoxetine), 
which are first-line treatments for depression, but also 
for other psychiatric conditions, such as anxiety, panic, 
and obsessive-compulsive disorders.17 Therapeutic 
ranges have also been proposed for these newer antide-
pressants4; however, as they have wider margins of safe-
ty in terms of overdose, as well as lower risks for side 
effects, the specificity and sensitivity are decreased for 
CYP genotyping tests in regard to prevention of side 
effects and/or increasing therapeutic response. Drug 
choice and/or dose adaptations made on the basis of 
CYP2D6 genotype have also been proposed for other 
antidepressants, such as SNRIs (eg, venlafaxine), and 
for typical (eg, perphenazine, thioridazine) and atypi-
cal antipsychotics (eg, risperidone, aripiprazole).17,20 
Of note, several studies found a higher prevalence of 
psychotropic drug–induced side effects associated with 
CYP activity, in particular with CYP2D6 PM status22-28; 
however, most studies investigating an association be-
tween CYP2D6 phenotype and/or genotype and treat-
ment response had negative results,29-31 though some 
had positive results.32
 CYP2C19 is also highly polymorphic with more than 
30 described variants, and allele frequencies are strong-
ly influenced by ethnicity. Similarly, PMs, IMs, EMs, and 
UMs have been described; the UM phenotype might 
arise from enhanced gene transcription resulting from 
the *17 allele, possibly increasing metabolism of anti-
depressants, such as citalopram and escitalopram.33 In 
addition, because the QT-inducing potential associated 
with these two drugs is higher than with other SSRIs, 
the CYP2C19 PM phenotype could be a risk factor in 
treatment with escitalopram.34 Higher amitriptyline 
and lower nortriptyline plasma concentrations were 
measured in CYP2C19 PMs and IMs than in EMs. Per-
sonalized prescribing of SSRIs according to CYP2C19 
genotype has also been proposed.35 The CPIC also 
made recommendations for amitriptyline dosing for 
combined CYP2D6 and CYP2C19 phenotypes; howev-
er, as clinical evidence for an additive effect of CYP2D6 
and CYP2C19 in tricyclic dosing is sparse, the recom-
mendations are classified as optional.
 CYP2B6 metabolizes a fewer number of compounds, 
which include methadone and bupropion among psy-
chotropic drugs. Its activity is also highly variable be-
tween individuals and within individuals because of 
genetic and environmental factors.36 CYP2B6 is highly 
polymorphic, with variants associated with multiple 
mechanisms (transcriptional regulation, splicing, mes-
senger RNA and protein expression, and catalytic activ-
ity).36 The simultaneous combinations of many variants 
producing multiple haplotypes, in addition to the large 
ethnic influence on CYP2B6 polymorphism, compli-
cates its analysis and the interpretation of results. Meth-
adone, a mu-opioid agonist used in pain treatment and 
for opioid-dependent patients, can prolong the QT in-
terval and carries a risk for ventricular tachyarrhythmia 
and Torsades de pointes. Methadone is marketed as a 
50%/50% mixture of (R)- and (S)-methadone, with few 
countries (eg, Germany, Austria, and Switzerland) cur-
rently having the pure (R)-enantiomer also available. 
(R)-methadone is the active form on opioid receptors, 
whereas (S)-methadone blocks more potently the hu-
man ether-à-gogo–related gene (hERG) voltage-gated 
potassium channel, which is responsible for QT-interval 
prolongation.37 (S)-methadone is metabolized preferen-
tially by CYP2B6, with multiple genetic polymorphisms 
helping to explain extreme (S)-methadone plasma lev-
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els.38 CYP2B6 slow metabolizers have longer corrected 
QT (QTc) intervals during methadone treatment, and 
slow CYP2B6 metabolism significantly increases the 
risk for a borderline or prolonged QTc interval (odds 
ratio, 6.3).37 In addition, the replacement of (R,S)-meth-
adone by a half dose of (R)-methadone significantly de-
creases the QTc interval in opioid-dependent patients 
treated with methadone.39 Prescription of (R)-metha-
done instead of the racemate, therefore, decreases (but 
does not abolish) methadone cardiotoxicity and should 
also decrease the influence of CYP2B6-decreased me-
tabolism. However, for a number of reasons, CYP2B6 
genotyping cannot substitute for an electrocardiogram 
in the prediction of cardiac arrhythmias and sudden 
death in methadone patients. Firstly, diminished CY-
P2B6 activity is associated with many variants and hap-
lotypes (several with yet unknown functions). Secondly, 
the presence of several pharmacodynamic heart genes 
and multiple other risk factors (eg, electrolyte distur-
bances, pharmaceutical or illicit drugs prolonging the 
QT interval and/or inhibiting methadone metabolism) 
may confound the conclusions.
 CYP1A2 is particularly involved in the metabolism 
of clozapine or olanzapine—two atypical antipsychot-
ics—and of duloxetine, an SNRI. Clozapine appears to 
be more promising than other drugs for personalized 
dosing because several studies have demonstrated an 
optimal plasma concentration for this drug; further-
more, high plasma levels are associated with a higher 
risk of convulsions.4 Some genetic CYP1A2 variants 
have been associated with low or high clozapine meta-
bolic activity,40,41 but these alleles are either rare or have 
low predictive value. Therefore, CYP1A2 genotyping is 
currently of little help for most patients. CYP1A2 activ-
ity is also controlled by other (non-CYP1A2) genetic 
factors, including the P450 oxidoreductase and nucle-
ar factors—such as constitutive androstane receptor 
(CAR), retinoid X receptor α (RXRa), pregnane X re-
ceptor (PXR), and vitamin D receptor (VDR)—which 
are involved in the regulation of constitutive and/or in-
ducible CYP1A2 activity.42-44 Genotyping of those addi-
tional genes adds little to predicting CYP1A2 variabil-
ity, possibly due to the influences of other genes and to 
the environmental influence on CYP1A2 activity. Thus, 
phenotyping tests (in vivo measurement of the activity 
using a probe substance, such as caffeine45) or TDM are 
more appropriate for personalized dosing of clozapine 
or of other CYP1A2-dependent drugs.
 Because of its abundance in the intestine and liver, 
CYP3A—a term that in adults reflects the collective ac-
tivity of CYP3A4, CYP3A5, and CYP3A7—is respon-
sible for the metabolism of more than 50% of marketed 
drugs. There is a large overlap of activity between CYP 
isoforms, potentially reducing the influence of CYP3A 
genetic heterogeneity on the pharmacokinetics of CY-
P3A-dependent drugs as a deficiency of one isoform 
may be partially compensated for by the activity of 
others. Although rare cases have been described of CY-
P3A PMs in which there is the simultaneous occurrence 
of mutations in different isoforms leading to very low 
or no CYP3A activity, genotyping is of little clinical rel-
evance46 unless the drug is preferentially metabolized 
by CYP3A5 (there is no known example in psychiatry). 
As is the case for CYP1A2, estimation of CYP3A activ-
ity is best measured by phenotyping tests, eg, performed 
with a very low oral dose of midazolam,45,47 such a test 
also integrating the modification of CYP3A activity by 
environmental factors.
 Other pharmacokinetic genes are not discussed in 
the present review, in particular ABCB1, which encodes 
for the permeability P-glycoprotein. Although ABCB1 
has been investigated in many studies for its influence 
on pharmacokinetics and on the response to psycho-
tropic drugs, mixed results have been published and 
evidence is lacking for the clinical use of ABCB1 geno-
typing in psychiatry.48,49 This gene is discussed in more 
detail in the companion article by Eum et al in this is-
sue. 
 In summary, pharmacokinetic genotyping can be 
useful in drug selection and/or for guiding dosing modi-
fications with the aim to personalize dosing. This is es-
pecially important for TCAs, which have a well-defined 
therapeutic window; nowadays, however, this class of 
drug is seldom prescribed for depression. Even if the 
impact of such tests is less important for other drugs, 
such a strategy is based on a sound and legitimate ob-
jective to reduce the interindividual variability in drug 
pharmacokinetics and the risks associated with extreme 
phenotypes. CYP genotyping appears more useful at 
the start of treatment than later on; after long-term 
treatment, the drug best adapted to a particular patient 
would possibly already have been selected through trial 
and error, and the drug dose already adapted accord-
ing to effect.7 However, some CYP isoform activity 
(eg, CYP1A2 or CYP3A) is poorly predicted by gene 
analysis and must be determined by phenotyping. Thus, 
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pharmacogenetic tests would not replace, but rather 
complement, other clinical tools, such as TDM, the lat-
ter combining the influence of environmental (eg, diet 
and/or taking of comedications that induce or inhibit 
activity), genetic (eg, CYP variants), and personal fac-
tors (eg, age, sex, weight, and illness) involved in metab-
olism and transport of drugs. Last but not least, TDM 
allows the measurement of active metabolites.1 
Pharmacodynamic genes for personalized 
drug selection
Genetic testing of pharmacodynamic factors is pres-
ently more promising for preventing rare idiosyncratic 
adverse drug reactions than for predicting treatment re-
sponse. Some recent findings linking pharmacogenetic 
factors with therapeutic response are interesting but 
need to be replicated.
Response to treatment and pharmacodynamic factors
Because of the common mechanism of many antide-
pressants—the inhibition of the reuptake of serotonin 
by the serotonin transporter—polymorphisms in the se-
rotonin-transporter-linked polymorphic region (5-HT-
TLPR) of the serotonin transporter gene (SLC6A4) 
have been extensively studied. In particular, the long 
(l)-allele is associated with a twofold higher expression 
than the short (s)-allele. Despite some discrepant re-
sults, a meta-analysis of 33 studies confirmed the associ-
ation between the (l)-allele and response to SSRIs and 
remission in whites, with sex, age, and age at onset of 
depression modulating the association.50 However, the 
clinical impact of SLC6A4 genotyping is modest, with a 
low odds ratio value (around 1.5), and therefore of little 
clinical help for predicting response. Other genes—in-
cluding serotonin receptors (5-hydroxytryptamine re-
ceptors 1A and 2A [HTR1A, HTR2A]); tryptophan hy-
droxylase (TPH1), involved in serotonin biosynthesis; 
serotonin transporter gene functional intron 2 (STin2), 
influencing serotonin transporter expression; and 
brain-derived neurotrophic factor (BDNF), probably 
involved in antidepressant action—may also modestly 
modulate antidepressant response.51 The hypothalamic-
pituitary-adrenal (HPA) axis has been implicated in 
antidepressant response; polymorphisms in the FK506 
binding protein 5 (FKBP5), which regulates glucocorti-
coid receptor sensitivity has been associated with rapid 
response to antidepressant treatment.52 However, this 
study was followed by others that in some cases sup-
ported these findings and in others did not.53
 Because dopamine is involved in the neurotrans-
mitter pathology of schizophrenia and because of the 
antagonist (all antipsychotics) or mixed agonist (ar-
ipiprazole) activity of antipsychotics on the dopamine 
D2 receptor, dopamine receptor and transporter genes 
have also been investigated. Polymorphisms in the D2 
receptor, in particular the -141Ins/Del polymorphism 
located in the promoter region, were associated with 
treatment response (lower response for Del allele) in 
a meta-analysis, but with a modest effect.54 Other sig-
nificant, but modest, associations were also found with 
other catecholamine systems, as well as glutamate and 
γ-aminobutyric acid (GABA) systems, although none 
of them could be considered clinically discriminant.55
 Although topiramate, an antiepileptic drug, has no of-
ficial indication for the treatment of alcoholism, it reduc-
es drinking and heavy drinking in individuals with alco-
hol dependence. Topiramate has multiple pharmacologic 
effects, including the facilitation of GABAergic function 
and antagonism of glutamate activity at the α-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid class of 
glutamate receptor (AMPA) and at kainate receptors, 
particularly for those containing GluK1 and GluK2 sub-
units (encoded by GRIK1 and GRIK2, respectively). 
The efficacy of topiramate for reducing heavy drinking 
was recently found to be significantly greater than pla-
cebo only in GRIK1 rs2832407 C-allele homozygotes.56 If 
these results are replicated, it would allow identification 
of heavy drinkers who would probably respond well to 
topiramate. This is important because there are only a 
few drugs available for alcoholism treatment, and they 
have limited success.
 A meta-analysis of three genome-wide association 
study (GWAS) analyses (GENDEP [GENome-based 
therapeutic drugs for DEPression], MARS [Munich 
Antidepressant Response Signatures], and STAR*D 
[Sequenced Treatment Alternatives to Relieve Depres-
sion]), examining the association with antidepressant 
drug response in 2256 individuals of Northern Euro-
pean descent with major depressive disorders, failed 
to identify reliable predictors of antidepressant treat-
ment.57 A recent GWAS was performed for lithium re-
sponse in bipolar 1 disorder with 294 patients of Han 
Chinese descent and replicated in two smaller groups.58 
Variations in the gene encoding glutamate decarboxyl-
317
P h a r m a c o l o g i c a l  a s p e c t s
ase–like protein 1 (GADL1) were found to be associ-
ated with response to lithium with an extraordinarily 
highly significant P value (P=10-37). The mechanism by 
which GADL1 would influence response is unknown, 
but its involvement in the biosynthesis of GABA is 
discussed. This finding has to be confirmed in Chinese 
patients, and other mutations have to be found in Cau-
casian and black African subjects (there is a low fre-
quency of the variant of interest in these two popula-
tions). Interestingly, a recent study pointed to a variant 
located in a methylated DNA immunoprecipitation se-
quencing (MeDIP-seq) site in the brain that may have 
exome-wide significance for treatment remission in 
depressed Mexican-Americans treated with fluoxetine; 
this finding suggests that this variant may be involved 
in epigenetic regulation of neuronal gene expression.59 
This study emphasizes the need for pharmacogenetic 
studies to include epigenetic factors.
Adverse events and pharmacodynamic factors
Concerning antipsychotics, dopamine receptor and 
transporter genes have also been investigated for asso-
ciations between genetic polymorphisms and antipsy-
chotic-induced side effects, eg, hyperprolactinemia, ex-
trapyramidal symptoms, and weight gain. Some results 
were inconsistent, whereas others were significant in 
meta-analyses only and were of low effect size as they 
needed a high number of patients to reach statistical 
significance. The discrepant results and/or the weak 
significant associations observed could be due, in part, 
to the proportions of classical (higher risk of hyperp-
rolactinemia and extrapyramidal symptoms) and atypi-
cal antipsychotics (higher risks of weight gain) differing 
between studies; thus, the described associations are of 
weak or modest predictive value.55 For antidepressants, 
genetic variations in serotoninergic mediators (eg, sero-
tonin transporter and receptors), as well as in intracel-
lular signal transduction pathways, have also been ex-
tensively studied.60 The results, when replicated, appear 
to be more related to tolerance and side effects than to 
the antidepressant response. Evidence and effect sizes 
that are sufficient to allow clinical applications are lack-
ing. 
 A large number of psychotropic drugs, including 
many antipsychotics (eg, clozapine or olanzapine), 
some mood stabilizers (eg, valproate), and some antide-
pressants (eg, mirtazapine), have been associated with 
substantial weight gain and/or other metabolic dysfunc-
tions (eg, obesity, hyperlipidemia, hypertension, and/or 
diabetes). Drug-induced weight gain and other meta-
bolic symptoms are of major clinical consequence as 
they contribute heavily to a marked decrease in life ex-
pectancy, with the natural mortality rate in psychiatric 
patients being 1.5- to 2-fold higher than in the general 
population, mainly due to a twofold higher prevalence 
of cardiovascular risk factors.61-63 Pharmacogenetics of 
psychotropic-induced weight gain has been extensively 
studied through hypothesis-driven candidate gene ap-
proaches. The polymorphisms that were the most stud-
ied and for which results were best replicated were in 
dopamine and serotonin receptors.64 Additionally, other 
genes implicated in leptin-melanocortin pathways (eg, 
leptin [LEP], leptin receptor [LEPR], melanocortin 
4 receptor [MC4R], and neuropeptide Y [NPY]), the 
endocannabinoid system (cannabinoid receptor type 
1 [CNR1]), or genes involved in fatty acid and cho-
lesterol production (scavenger receptor class B type I 
[SCARB1], insulin-induced gene 2 [INSIG2]) showed 
an association with weight gain among psychiatric co-
horts treated with antipsychotics.65 Recently, research 
conducted in our department showed other candidate 
genes coding for enzymes involved in metabolic path-
ways (phosphoenolpyruvate carboxykinase 1 [PCK1], 
11β-hydroxysteroid dehydrogenase [11βHSDW1]), 
for receptors (melanin concentrating hormone re-
ceptor 2 [MCHR2]), and for transcriptional coactiva-
tors (CREB-regulated transcriptional coactivator 1 
[CRTC1]) involved in energy balance, appetite regula-
tion, and glucose homeostasis.66-69 There is less informa-
tion on genes associated with antipsychotic-induced 
diabetes mellitus and hyperlipidemia. A recent GWAS 
(N=189) identified no associations with antipsychotic-
induced weight gain at the genome-wide threshold, but 
trends for some variants were observed, variants that 
should be investigated further.70 The occurrence of met-
abolic effects can be best predicted by a combination of 
clinical factors (eg, age and baseline body mass index) 
with multiple genetic factors, possibly aggregated in ge-
netic risk scores.71 However, the value of such combina-
tions in clinical practice remains to be determined.
 Presently, the drug in psychiatry with probably the 
most compelling evidence in support of pharmacoge-
netic testing is carbamazepine, an anticonvulsant and a 
mood-stabilizer drug. It can cause Stevens–Johnson syn-
drome (SJS) or toxic epidermal necrolysis (TEN) reac-
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tions, which occur in about 1 to 6 per 10 000 new users in 
the white population, but the risk is strongly increased 
in Asian patients. In Asians, major histocompatibility 
complex, class I, B, allele 1502 (HLAB*1502 allele) is 
a predictor of SJS-TEN, with an extraordinarily high 
odds ratio (odds ratio, 1357, P=1.6*10-41).72 The FDA re-
quires that Asian patients be screened for the presence 
of HLA-B*1502 before initiating carbamazepine treat-
ment. Because this allele is also present in patients with 
non-Asian ancestry, and because Asian ancestry can 
neither be deduced from the family name nor from the 
physical appearance, the extension of these analyses in 
all patients has been advocated.73 Patients carrying this 
allele should not be treated with carbamazepine unless 
the benefit clearly outweighs the risk. In a prospective 
screening for HLA-B*1502 before prescription of car-
bamazepine in 4877 Asian patients, no SJS-TEN case 
was observed in the HLA-B*1502-negative patients, 
whereas 10 cases were expected, based on historical 
incidence, without screening.74 The HLA-A*3101 allele 
has been proposed as a clinically relevant marker to 
predict hypersensitivity reactions to carbamazepine in 
whites and Japanese, but has low sensitivity. The posi-
tive predictive value and negative predictive value for 
a HLA-B*1502 screening test in Asians is 1.8% (7.7% 
in Han only) and 100%, respectively, with 461 patients 
needing to be tested to prevent one case of SJS-TEN,73 
which is a favorable cost:benefit ratio considering the 
present cost of genotyping and the severity of the syn-
drome. The low positive predictive value (referring to 
the proportion of patients who test positive for HLA-
B*1502 and who then develop SJS-TEN) means that 
many carriers would not suffer from SJS-TEN, which is 
theoretically not a major concern because other phar-
macological alternatives are available. However, the 
high negative predictive value (referring to the propor-
tion of patients who test negative for HLA-B*1502 and 
who do not develop SJS-TEN) is valuable when making 
a decision to select carbamazepine. Lamotrigine, an an-
tiepileptic drug also used for the treatment of depres-
sion in bipolar disorders, can also cause TEN. Although 
lamotrigine-induced TEN has also been associated with 
variants of the human leukocyte antigen (HLA) system, 
there are presently insufficient data to justify HLA ge-
netic testing for lamotrigine treatment.5
 Clozapine is considered the most efficient antipsy-
chotic in resistant schizophrenia.75 Because of the risk 
of agranulocytosis, it is licensed for use only in schizo-
phrenic patients whose illness has not responded ad-
equately to standard treatment. Other variants of HLA 
(eg, HLA-DQB1 and HLA-B) have been associated 
with clozapine-induced agranulocytosis and could be 
useful in identifying patients at high risk.76,77 However, 
considering a positive genetic test, if an individual car-
ried either risk factor, the sensitivity and specificity of 
the test would be 0.36 and 0.89, with more than half of 
cases not carrying the two risk factors.77 Theoretically, 
a genetic test for clozapine needs a high positive pre-
dictive value because patients must not be denied a 
treatment while there are no, or only few, alternatives. 
In addition, a high negative predictive value is needed 
to propose pharmacogenetic tests as an alternative to 
white blood cell monitoring. The usefulness of pharma-
cogenetic tests for clozapine must therefore be reas-
sessed in the future, with the discovery of other genetic 
risks, and possibly also protection factors, increasing the 
negative and positive predictive value.
Perspectives
The use of pharmacogenetics in psychiatry is already 
challenging because of factors associated with the 
complexity of psychiatric illness, a high prevalence of 
comorbidites, difficulties in classification, and overlap-
ping phenotypes. In addition, there are no valid and 
reliable diagnostic and prognostic biological markers, 
in contrast with other diseases (eg, blood glucose levels 
for type 2 diabetes).78 Finally, psychiatric diseases are 
polygenic (a recent GWAS study identified 128 inde-
pendent associations from 108 defined loci with schizo-
phrenia79).
Concerning pharmacokinetic genes, dose recommen-
dations according to CYP genotypes have been pub-
lished for several psychotropic drugs. However, due to 
the low sensitivity of the tests, a very high number of 
patients must be genotyped to prevent one case of se-
vere side effect and/or nonresponse. This can explain, 
in conjunction with the low specificity of the tests and 
the present cost of genetic analysis, why genotyping of 
pharmacokinetic factors such as CYP isoforms is pres-
ently mostly done in psychiatry on a retrospective basis 
to understand unusual drug responses. In addition, the 
activity of specific isoforms (ie, activity of CYP1A2 and 
CYP3A) cannot be reliably used because of the mul-
tigenic and environmental influences. However, drug 
selection and dose recommendations made on the ba-
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sis of CYP activity (determined by genotyping and/or 
phenotyping) remains a legitimate objective. Concern-
ing pharmacodynamic genes, there is presently only one 
for which there is strong evidence in favor of proposing 
testing on a routine basis (HLA-B*1502 for carbamaze-
pine). New pharmacogenetic factors using SNP analy-
sis will be discovered in the future, but the influence of 
other sources of variability—including genetic factors 
(eg, copy number variants and microRNA), as well as 
epigenetic factors (eg, histone deacetylation and gene 
methylation)—must be taken into account.57-80 Because 
of the very rapid technological advances and the sharp-
ly diminishing costs of genetic analysis, pharmacoge-
nomic testing is increasingly used nowadays. However, 
the substantial differences in the levels of evidence 
between markers, combined with the low sensitivity 
and/or specificity for the large majority of them, has to 
be taken into account. Pharmacogenetic tests are not 
magic bullets and to be clinically useful they need to 
be incorporated into a comprehensive pharmacological 
knowledge of the drug, which includes its pharmacoki-
netics and pharmacodynamics, its therapeutic window, 
and its idiosyncratic and dose-related adverse drug 
reactions. Only when combined with careful clinical 
evaluation—with the help of other tools, such as TDM 
and/or phenotyping tests—can pharmacogenetics con-
tribute to the general aim of providing the best care for 
psychiatric patients.  o
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Prescripción personalizada: un nuevo modelo 
médico para el uso clínico de los psicofármacos 
Dada la influencia de los factores genéticos en la far-
macocinética y farmacodinámica de los medicamentos, 
el amplio empleo de pruebas farmacogenéticas en psi-
quiatría ya ha sido propuesta desde los comienzos de 
los años 2000. Sin embargo, sólo unas pocas pruebas 
(ej. HLA-B*1502 para la carbamazepina en epilepsia o 
trastornos bipolares) han alcanzado niveles de eviden-
cia para justificar su uso rutinario, mientras que muchos 
hallazgos son demasiado preliminares o, cuando se han 
replicado, son  de baja relevancia clínica debido a la 
reducida magnitud del efecto. Si bien la selección del 
fármaco y el ajuste de dosis de acuerdo con los genoti-
pos de los citocromos P 450 están justificados, un gran 
número de pacientes necesitan ser genotipados para 
prevenir un caso de efecto secundario grave y/o de no 
respuesta. La disminución de los costos de los análisis 
genéticos modifica la relación costo-beneficio a favor 
de un aumento del empleo de las pruebas farmacoge-
néticas. Sin embargo, ellas tienen que combinarse con 
evaluaciones clínicas cuidadosas y otras herramientas 
(ej. monitoreo de drogas terapéuticas, fenotipado) para 
contribuir al objetivo general de proporcionar la mejor 
atención para los pacientes psiquiátricos.  
Prescription personnalisée : un nouveau modèle 
médical pour la mise en place des psychotropes 
Les facteurs génétiques influant sur la pharmacociné-
tique et la pharmacodynamique des médicaments, l’utili-
sation de tests pharmacogénétiques a déjà été proposée 
en psychiatrie dès le début des années 2000. Cependant, 
seuls quelques tests bénéficient de niveaux de preuve 
suffisants pour justifier leur utilisation en routine (par 
exemple, complexe majeur d’histocompatibilité, classe I, 
B, allèle 1502 [HLA-B*1502] pour la carbamazépine dans 
l’épilepsie et les troubles bipolaires) ; de nombreux ré-
sultats, lorsqu’ils sont reproduits, sont trop préliminaires 
ou n’ont finalement qu’une pertinence clinique limitée 
en raison de la faible ampleur de leur effet. Le choix des 
médicaments et l’adaptation posologique selon les géno-
types des cytochromes P450 sont des démarches sensées 
mais il faut génotyper un grand nombre de patients pour 
prévenir un cas d’effet indésirable sévère et/ou d’absence 
de réponse. La diminution des coûts de l’analyse géné-
tique a orienté le rapport coût/bénéfice vers une plus 
large utilisation des tests pharmacogénétiques. Ils doivent 
néanmoins être associés à un examen clinique soigneux 
et à d’autres moyens (par exemple, suivi thérapeutique 
des médicaments et phénotypage) afin d’apporter les 
meilleurs soins aux patients psychiatriques.
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